Background Epidermal growth factor receptor (EGFR) mutation positive (M+) non‐small cell
lung cancer (NSCLC) is an important subtype of lung cancer comprising 10% to 15% of non …

Neuropathy is a common, often debilitating complication of cancer and its treatment.
Effective management of this disorder depends on early diagnosis and an understanding of …

The purpose of this article is to provide updated recommendations for the treatment of
patients with stage IV non–small-cell lung cancer. A literature search identified relevant …

Purpose This multicenter phase II study was undertaken to investigate the efficacy and
feasibility of gefitinib for patients with advanced non–small-cell lung cancer (NSCLC) …

Background Performance status (PS) is an important factor in determining survival outcome
in non-small cell lung cancer (NSCLC) but is generally confounded by stage, age, gender …

Purpose To compare single-agent pemetrexed (P) versus the combination of carboplatin
and pemetrexed (CP) in first-line therapy for patients with advanced non–small-cell lung …

Introduction Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …

Purpose Erlotinib is clinically effective in patients with non–small-cell lung cancer (NSCLC)
who have adenocarcinoma, are never or limited former smokers, or have EGFR mutant …

Early clinical studies of tyrosine kinase inhibitors (TKIs) that target the EGFR in patients with
advanced non-small-cell lung cancer (NSCLC) showed that some patients experienced …

Background Many patients with advanced non-small-cell lung cancer (NSCLC) receive only
active supportive care because of poor performance status or presence of several …